ArticleScientific reports2021
The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Methodological challenges in surgical randomized trials: systematic review of rectal cancer studies.BJS open · 2026Pooled it
- The effect of a person-centred lifestyle programme on cancer-related fatigue in colorectal cancer survivors: a randomised trial.The British journal of nutrition · 2026Trial
- Article
- Health-related quality of life and functional outcomes of colon cancer patients in the Netherlands: A population-based study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Observational
- Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer.Acta oncologica (Stockholm, Sweden) · 2026Article
- Dietary and lifestyle inflammation scores in relation to colon cancer recurrence in subgroups of patients based on common molecular tumour characteristics.ESMO gastrointestinal oncology · 2025Article
- Assessing the representativeness of large medical data using population stability index.BMC medical research methodology · 2025Article
- Improving sustainability of a patient decision aid for systemic treatment of metastatic colorectal cancer: A qualitative study.PEC innovation · 2024Article
- A scenario-drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology.Molecular oncology · 2024Article
- Mechanisms of metastatic colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.British journal of cancer · 2024Article
- Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer.ESMO open · 2024Article
- Article
- Limited wedge resection for T1 colon cancer (LIMERIC-II trial) - rationale and study protocol of a prospective multicenter clinical trial.BMC gastroenterology · 2023Article
- The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections.BMC medical research methodology · 2023Article
- Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the "real-world". Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013-2016 and 2017-Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64-0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017-Aug'19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC's representativeness and its contribution to a learning healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.